Molecular Partners (MOLN) said late Wednesday that updated data from a phase 1/2a study of MP0533 showed three out of eight patients with relapsed or refractory acute myeloid leukemia responded after the first cycle of a steeper step-up dosing in group eight.

One patient in the group achieved a complete response, while the remaining two patients had a complete response with partial hematologic recovery, the company said.

The company said it is dosing patients in group nine and expects data from the amended dosing scheme in H2.